H&E staining of tumour sections revealed more prominent morphological changes that were characterised by more extensive mucinous differentiation, lower overall cell density, and fewer cancer cells in metronomic gemcitabine-treated tumours compared with their MTD-treated counterparts.
These locations are outside the genomic regions previously identified as being genetically differentiated in the M and S forms [4], [8], [9], [16], 17, 19 (see Fig. 7), suggesting either that the chromosomal regions involved in this differentiation are more extensive than expected, or that there are additional differentiated regions interspersed with undifferentiated regions.
Loss of membranous E-cadherin expression was more extensive in poorly differentiated carcinomas while, in individual carcinomas, membranous E-cadherin expression was stronger in those parts of the neoplasm that expressed the differentiation marker involucrin.
Compared with the serum effect, medium B also permitted neurosphere attachment onto the substrate surface and cell migration out of neurospheres extensively, but enhanced more extensive cell division and slowed down NSPC differentiation to generate a confluent NSPC monolayer.
The functional significance and regulation of this event remain to be elucidated; however, RBM6-RBM5 chimeric transcripts could prove to be useful tumour differentiation markers, although more extensive expression analyses are required to confirm these observations.
PDTC has some loss of differentiation, while ATC has more extensive loss.
This is supported by our data showing that during differentiation, cleavage of STAT3α is more extensive.
High PXN expression was positively associated with larger tumor size (P = 0.020), adverse differentiation status (P = 0.023), more extensive lymph node invasion (P = 0.002) and higher TNM stage (P = 0.001).
HRG4 was designed to evolve year on year, but in 2012/13 a more extensive update, referred to as HRG4+, provided even greater differentiation for complications and co-morbidities [7].
